Phaseline

Companies › Shanghai Exuma Biotechnology

Shanghai Exuma Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
C402-CD19-CAR
Anti-CD19 CAR-T cell therapy
CD19Phase 1Diffuse Large B-cell-lymphomaApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06830031C402-CD19-CARPhase 1Diffuse Large B-cell-lymphomaOncologyApr 2029

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.